Viewing Company
Company Name:
NYMOX PHARMACEUTICAL CORPORATION
CIK:
1018735
Phone:
None
Fiscal Year End:
None
Entity Type:
SIC:
-
Category Type:
Entity Name:
None
First Filing Date:
2018-03-30
Last Filing Date:
2025-01-02
SEC Filings
| Start | End | Frame | Filed | ACCN | Value | View |
|---|---|---|---|---|---|---|
| 2021-01-01 | 2021-12-31 | CY2019 | 2022-03-30 | 0001640334-22-000622 | $ -12,537,000 | View |
| 2019-07-01 | 2019-09-30 | CY2018Q3 | 2019-11-13 | 0001640334-19-002273 | $ 69,974,000 | View |
| 2023-01-01 | 2023-03-31 | CY2023Q1 | 2023-05-12 | 0001640334-23-000844 | $ 61,000 | View |
| 2020-07-01 | 2020-09-30 | CY2019Q3 | 2020-11-13 | 0001640334-20-002804 | $ 74,699,000 | View |
| 2021-01-01 | 2021-03-31 | CY2020Q1 | 2021-05-14 | 0001640334-21-001149 | $ 77,969,000 | View |
| 2022-01-01 | 2022-03-31 | CY2022Q1I | 2022-05-13 | 0001640334-22-000990 | $ 329,000 | View |
| 2019-01-01 | 2019-03-31 | CY2018Q1 | 2019-05-15 | 0001640334-19-000882 | $ 67,046,000 | View |
| 2019-04-01 | 2019-06-30 | CY2018Q2 | 2019-08-14 | 0001640334-19-001644 | $ 68,436,000 | View |
| 2020-01-01 | 2020-03-31 | CY2019Q1 | 2020-05-14 | 0001640334-20-001197 | $ 71,598,000 | View |
| 2020-04-01 | 2020-06-30 | CY2019Q2 | 2020-08-14 | 0001640334-20-002150 | $ 71,730,000 | View |
| 2020-01-01 | 2020-12-31 | CY2018 | 2021-03-29 | 0001640334-21-000680 | $ 73,823,000 | View |
| 2021-04-01 | 2021-06-30 | CY2020Q2 | 2021-08-13 | 0001640334-21-001859 | $ 81,490,000 | View |
| 2021-07-01 | 2021-09-30 | CY2020Q3 | 2021-11-12 | 0001640334-21-002755 | $ 83,752,000 | View |
| 2018-01-01 | 2018-03-31 | CY2017Q1 | 2018-05-15 | 0001640334-18-001003 | $ 57,056 | View |
| 2022-04-01 | 2022-06-30 | CY2021Q2 | 2022-08-15 | 0001640334-22-001775 | $ 3,117,000 | View |
| 2022-01-01 | 2022-09-30 | CY2021Q3 | 2022-11-16 | 0001640334-22-002477 | $ 177,000 | View |
| 2022-01-01 | 2022-12-31 | CY2022 | 2023-05-02 | 0001640334-23-000736 | $ 0 | View |
| 2023-04-01 | 2023-06-30 | CY2023Q2 | 2023-08-14 | 0001640334-23-001575 | $ 10,000 | View |
| 2023-01-01 | 2023-09-30 | CY2022Q3 | 2023-11-15 | 0001640334-23-002155 | $ -1,000,000 | View |
| 2024-01-01 | 2024-09-30 | CY2024Q3I | 2025-01-02 | 0001640334-25-000006 | $ 2,606,000 | View |
| 2023-01-01 | 2023-12-31 | CY2023 | 2024-08-29 | 0001640334-24-001383 | $ -1,000 | View |
| 2017-01-01 | 2017-12-31 | CY2015 | 2018-03-30 | 0001640334-18-000561 | $ 139,000 | View |
| 2017-01-01 | 2017-12-31 | CY2016 | 2019-03-29 | 0001640334-19-000464 | $ 139,000 | View |
| 2018-04-01 | 2018-06-30 | CY2018Q2 | 2018-08-13 | 0001640334-18-001545 | $ 935,000 | View |
| 2018-07-01 | 2018-09-30 | CY2018Q3 | 2018-11-13 | 0001640334-18-002114 | $ 1,171,000 | View |
| 2017-01-01 | 2018-12-31 | CY2018Q4I | 2020-03-30 | 0001640334-20-000668 | $ 17,000 | View |
SEC Facts By Type
| Type | Name | Description | View |
|---|---|---|---|
| dei | Entity Common Stock, Shares Outstanding | Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. | View |
| ifrs-full | 1459546 | None | View |
| us-gaap | Accretion Expense | Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations. | View |
| us-gaap | Convertible Debt | Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. | View |
| us-gaap | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. | View |
| us-gaap | Operating Lease, Liability | Present value of lessee's discounted obligation for lease payments from operating lease. | View |
| us-gaap | Security Deposit | The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. | View |
| dei | Entity Public Float | The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. | View |
| us-gaap | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). | View |